Post by
wildbird1 on Jul 18, 2024 12:11pm
Clinical Study Site (CSSs) ...
In the last 1Q2024 Financial Statement for the months of Jan, Feb,and March 2024...
Under BTD update...
TLT said '' TLT has commenced receiving clinical data from the CSSs(Clinical Study Site, collecting data for the FDA). And a number of patients, showing a duration of their CR beyond 450 days, with some patients demonstrating CR up to 3 years.''
The above indicate that the data received so far are very positive.
If TLT commenced receiving the CSSs data in Jan 2024, it does mean that as we speak, TLT could have been receiving back the CSSs data that the FDA asked TLT to provide for the last 7 months.
Question? How close is TLT from reaplying for Pre-BTD and BTD approval?
I have no idea, but we know one things for sure.
You can receive back a lots of data in 7 months.
It is a dangerous time to be without your TLT shares.
Hold on to your TLT shares.
Comment by
Lesalpes29 on Jul 18, 2024 12:33pm
Did my part to help TD investors, added 24k shares! .17 seems to be an ok price! GL
Comment by
Alamir1111 on Jul 18, 2024 4:10pm
https://www.cancer.gov/research/participate/clinical-trials/disease/bladder-cancer/treatment?pn=1